Loading company
Immunocore Holdings plc
IMCR · Nasdaq · ·
Next earnings: November 5, 2026
$30.76+0.5%Sep 29 close
- 1M
- -16.0%
- 6M
- +5.0%
- 1Y
- -15.3%
- 5Y
- -11.5%
IMCR · Nasdaq · ·
Next earnings: November 5, 2026
$30.76+0.5%Sep 29 close
Immunocore Holdings plc is scheduled to report next on November 5, 2026. The date comes from Nasdaq’s earnings calendar, and companies sometimes move it.
The quarter ending June 30, 2026, against the same quarter a year earlier.
| Measure | 3 months toJun 30, 2026 | 3 months toJun 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $115.9M | $98M | +18.34% |
| Profit | -$808K | -$10.3M | +92.16% |
| Profit per share | -$0.02 | -$0.20 | +90.00% |
| Free Cash Flow | $15.1M | $25.6M | -40.74% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
“The five-year overall survival data for KIMMTRAK underscores the lasting impact of our medicine for patients with metastatic uveal melanoma and reinforces our confidence in the potential of our platform,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land after the close or before the open, so the move is the session that follows.
TM molecules and autoimmune diseases ImmTAAI (Immune mobilizing monoclonal TCRs Against AutoImmune disease) molecules are novel bispecifics that are designed for tissue-specific down modulation of the immune system. When tethered to the tissue of interest, ImmTAAI candidates suppress pathogenic T cells via PD1 receptor agonism. The Company is currently advancing two candidates for autoimmune diseases, including type 1 diabetes and inflammatory dermatological diseases.
The company’s own description, as it appears at the foot of the release.
The quote and the company description come from Immunocore Holdings plc’s Item 2.02 8-K filed August 6, 2026; the table is built from its quarterly reports. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Immunocore Holdings plc has no earnings call transcript available.